

Guillaume Richard-Carpentier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/695025/publications.pdf>

Version: 2024-02-01

18
papers

437
citations

687363

13
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

762
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 212-218.	0.4	71
2	Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071988282.	2.5	52
3	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	4.6	43
4	Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. <i>Blood</i> , 2019, 134, 263-276.	1.4	41
5	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2019, 134, 678-678.	1.4	26
6	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. <i>Nature Medicine</i> , 2022, 28, 557-567.	30.7	26
7	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, 543-545.	2.5	24
8	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419.	5.2	24
9	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. <i>Leukemia</i> , 2020, 34, 872-881.	7.2	22
10	Single-agent and combination biologics in acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 548-556.	2.5	22
11	Recent Advances in Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 106-118.	2.3	21
12	Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. <i>Blood Cancer Journal</i> , 2020, 10, 47.	6.2	17
13	A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2018, 132, 32-32.	1.4	14
14	Impact of <i>CD33</i> and <i>ABCB1</i> single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. <i>American Journal of Hematology</i> , 2020, 95, E225-E228.	4.1	9
15	Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1292-1305.	2.8	8
16	Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet?. <i>Cell Stem Cell</i> , 2017, 20, 300-301.	11.1	7
17	Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin. <i>CEN Case Reports</i> , 2020, 9, 147-151.	0.9	5
18	Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. <i>Blood Advances</i> , 2021, 5, 3913-3918.	5.2	5